

Company name Circuit-Bio LTD

* Website <https://circuitbiotech.com/>

* CEO name Dr. Nir Skalka

CATEGORY: Biotech/Pharma or Medical Devices or Health IT/Digital *

SESSIONS • Next generation of genetic medicine • Evolving trends in cancer therapeutics Y

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity. Circuit-Bio is a pre-clinical stage synthetic biology company developing a unique tumor-specific gene circuits platform for cancer immunotherapy. The company's gene circuit is encoded upon a virus and can be administered systemically or locally.

o Core Technology What is the technology, its uniqueness, and its value proposition? Circuit-Bio pioneers a transformative immunotherapy modality that enables exceptional selective expression of immunomodulators in solid tumors' micro-environment for a dramatic increase of the therapeutic window. This novel technology utilizes an intracellular dual-verification mechanism to selectively recruit the tumor itself to stimulate the immune system and trigger an anti-tumor response.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. The company's base technology is relevant to many different types of cancer and therapeutic indications. Currently, the company is focusing on melanoma, breast and colorectal cancer, with the goal of initiating First-in-Human trials by the end of 2026. Within the company's pipeline, the lead program CRC213 exhibited in vitro and in vivo high specificity and efficacy toward colorectal tumors.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. The company's partners include RMG Global, J&J DC, Leaps (Bayer), OrbiMed, and Takeda. The current year (2024) will be dedicated to Series A fundraising to expand the company's investor base, which will help support ongoing platform and product development throughout clinical trials. o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans The company is focusing on promoting the lead product CRC213 for colorectal cancer through the completion of Phase I/II (FIH single and multiple doses) by Q1, 2028. Simultaneously, to develop and expand the company's pipeline for other therapeutic indications.